Nanobody-liposomes as novel cancer vaccine platform to efficiently stimulate T cell immunity
Rianne G. Bouma, Maarten K. Nijen Twilhaar, Hendrik J. Brink, Alsya J. Affandi, Bárbara Mesquita, Katarzyna Olesek, J.M.A. van Dommelen, Raimond Heukers, Alexandra Haas, Hakan Kalay, Martino Ambrosini, Josbert M. Metselaar, Anita Van Rooijen, G. Storm, S. Oliveira, Yvette van Kooyk, Joke M. M. den Haan
Abstract
Cancer vaccines can be utilized in combination with checkpoint inhibitors to optimally stimulate the anti-tumor immune response. Uptake of vaccine antigen by antigen presenting cells (APCs) is a prerequisite for T cell priming, but often relies on non-specific mechanisms. Here, we have developed a novel vaccination strategy consisting of cancer antigen-containing liposomes conjugated with CD169- or DC-SIGN-specific nanobodies (single domain antibodies) to achieve specific uptake by APCs. Our studies demonstrate efficient nanobody liposome uptake by human and murine CD169+ and DC-SIGN+ APCs in vitro and in vivo when compared to control liposomes or liposomes with natural ligands for CD169 and DC-SIGN. Uptake of CD169 nanobody liposomes resulted in increased T cell activation by human APCs and stimulated naive T cell priming in mouse models. In conclusion, while nanobody liposomes have previously been utilized to direct drugs to tumors, here we show that nanobody liposomes can be applied as vaccination strategy that can be extended to other receptors on APCs in order to elicit a potent immune response against tumor antigens.